Phosphatidylserine and Memory: What the Evidence in Older Adults Shows

September 3, 2026

Phosphatidylserine gets marketed broadly as a "brain booster," but the actual trial evidence is narrower and more specific than that phrase suggests — which, in this case, is a point in its favor rather than against it. The trials that hold up are almost all run in the same population: older adults already showing signs of cognitive decline, tested for months at a time, on a fairly specific dose range. That's a much more useful thing to know than "supports brain health."

Correction notice (September 2026): This article carried five errors, now corrected. (1) It said the FDA had issued "a string of 'no questions' GRAS determinations" for phosphatidylserine, "most recently a 2019 sunflower-derived PS notice." That is the reverse of what happened: the sunflower phosphatidylserine notice (GRN 636) was filed in March 2016 and closed that July with FDA stating it "ceased to evaluate this notice" at the notifier's request. There is no FDA clearance letter for it. (2) It described the intended use as "up to 300mg per serving in medical foods"; the notice specified up to 300mg daily in medical foods. (3) It gave fatty-acid composition figures for soy and sunflower PS (‘62%’ and ‘70%’ linoleic acid) sourced only to an FDA document now unavailable at the cited address; being unverifiable, they have been removed rather than replaced with a guess. (4) It said the pooled meta-analysis found "no significant adverse effects"; the authors in fact reported minor adverse events including flatulence and nausea, and found no benefit at all on activities of daily living. (5) Most importantly, it described the 12-month trial as testing phosphatidylserine at a low dose. The trial tested a multi-ingredient capsule in which PS was a minor component by weight — its results cannot be attributed to phosphatidylserine, and the inference we drew from it about low-dose PS has been withdrawn. A claim about Cognitive Support's ingredient disclosure has also been corrected.

What the trial evidence actually covers

A 2022 systematic review and meta-analysis in the Korean Journal of Food Science and Technology pooled nine studies — five randomized controlled trials and four pre-post studies, 961 participants total — testing phosphatidylserine doses of 100–300mg/day over periods ranging from 6 weeks to 6 months.¹ The population wasn't healthy young adults looking for an edge; it was older adults already experiencing cognitive decline. Within that population, the pooled effect on memory was statistically significant but small: a standardised mean difference of 0.22 (95% CI 0.06 to 0.38, p<0.01), on evidence the authors graded as moderate quality.

Three things in that review deserve more airtime than they usually get. First, the benefit did not extend to activities of daily living — a null result, with conflicting findings between studies. Second, minor adverse events were reported, including flatulence and nausea, though the authors couldn't confirm causality. Third, three of the nine studies gave phosphatidylserine combined with DHA and EPA, so part of the pooled signal isn't attributable to PS on its own. An SMD of 0.22 is a real effect. It is also a modest one, and worth putting next to the omega-3 cognitive-aging literature before deciding where to spend money.

961 people, 9 studies

The pooled meta-analysis behind phosphatidylserine's memory effect used doses of 100–300mg/day for 6 weeks to 6 months, and found a small but significant memory benefit (SMD 0.22, 95% CI 0.06–0.38) — with no benefit on activities of daily living.¹

Memory specifically, not "cognition" broadly

This is the detail most marketing drops: the benefit clustered on memory, not on a broad basket of cognitive domains. That's a more specific and more credible claim than "supports brain function" — it also means the evidence doesn't clearly support using phosphatidylserine as a general nootropic for a healthy adult with no cognitive complaints, since that's not the population or outcome the trials were built around. If what's prompting your interest is memory slips rather than a diagnosis, our piece on what's normal ageing and what needs an assessment is the more useful first read.

The source question: soy, sunflower, and a discontinued original

Here's a wrinkle that most product pages skip entirely. The earliest body of phosphatidylserine research — including the 1980s and 1990s studies that fed into the meta-analysis above — used PS extracted from bovine (cow) brain cortex. That ingredient largely disappeared from the market after concerns about bovine spongiform encephalopathy (BSE, "mad cow disease") prion contamination made animal-brain-derived ingredients a hard sell to regulators and manufacturers alike; the review's authors note explicitly that bovine-derived PS research declined for this reason, with soy and marine sources becoming the predominant alternatives.¹ What's sold today is overwhelmingly plant-derived PS, made by enzymatically converting the phospholipids in soy or sunflower lecithin into phosphatidylserine.

Soy- and sunflower-derived PS are not identical to each other, and neither is identical to the original bovine version, whose fatty-acid profile included some DHA. The specific fatty-acid percentages for the two plant sources that this article previously printed traced back to a single FDA document that is no longer retrievable at its cited address, so we've removed them rather than repeat a number we can't check. What we can say from the regulatory record is narrower, and worth knowing precisely, because it's usually reported wrongly.

The one phosphatidylserine notice in FDA's GRAS inventory that we could locate is GRN 636, "Phosphatidylserine derived from sunflower lecithin," notified by ECA Healthcare, Inc. It was filed on 29 March 2016 and closed on 1 July 2016, with FDA recording that "at the notifier's request, FDA ceased to evaluate this notice."² That is a withdrawal, not a clearance: there is no FDA "no questions" letter behind sunflower PS. The intended conditions of use described in the filing were up to 100mg per serving in dairy analogues, grain products, milk products and fruit juices, 50mg per serving in breakfast cereals and fluid milk, and up to 300mg daily in medical foods. That's what the notifier proposed — not what a regulator endorsed.

Source	Status today	Notes
Bovine cortex PS	Effectively discontinued	Original research substrate; research declined over BSE prion-contamination concerns¹
Soy-derived PS	Widely sold	Became the predominant commercial source from the 2000s onward¹
Sunflower-derived PS	Sold; GRAS notice withdrawn	Soy-free alternative; GRN 636 was closed in 2016 without FDA completing its evaluation²

None of this means soy or sunflower PS "doesn't work" — the dose levels used in the clinical trials are the ones in the meta-analysis above, and the trials in the 2000s onward largely used plant-derived material. But it's a real distinction worth knowing if you're comparing labels: "phosphatidylserine" alone doesn't tell you which plant it came from, the bovine-derived form behind some of the earliest headlines isn't what's in a bottle today, and "FDA GRAS" is a phrase worth checking rather than taking on trust. This is the same habit we recommend for reading a supplement label generally.

A longer, newer trial — and why it isn't a phosphatidylserine trial

Most of the classic phosphatidylserine trials ran for a few months at most. A randomized, double-blind, placebo-controlled trial published in the Journal of Affective Disorders extended that window considerably: 190 older adults in Tianjin, China (mean age 67.95, 63% female) with diagnosed mild cognitive impairment took two capsules daily for a full 12 months.³

Read the capsule composition before drawing any conclusion about phosphatidylserine from it. Each capsule contained 144mg alpha-linolenic acid, 31.5mg phosphatidylserine and 3.6mg Ginkgo total flavonoids, plus 0.48mg vitamin B1, 0.48mg vitamin B6 and 90µg folic acid. By weight the dominant active was ALA at 288mg/day, with PS at 63mg/day and ginkgo alongside it. This is a multi-ingredient trial, and its results cannot be assigned to phosphatidylserine.

What it found: compared with placebo, the intervention group improved significantly on arithmetic testing (β 0.688, 95% CI 0.103–1.274), a similarity/abstraction test (β 1.070, 0.472–1.667) and short-term memory (β 0.600, 0.399–0.800), with significant rises in serum ALA, DHA, EPA, acetylcholine, GABA and serotonin.³ A causal mediation analysis found the intervention may improve short-term memory by raising serum ALA, with a mediation proportion of 19.7% — in other words, the mechanism the authors were able to trace runs through the omega-3, not the phosphatidylserine. An earlier version of this article treated the trial as evidence that a low PS dose works if sustained long enough. It isn't, and we've withdrawn that inference.

Key takeaway: The clearest phosphatidylserine evidence sits in older adults with diagnosed cognitive decline, at doses of roughly 100–300mg/day for six weeks to six months, with memory as the specific outcome and a small effect size — not in healthy adults looking for a general cognitive edge, and not at the low doses used inside multi-ingredient formulas.

Phosphatidylserine's evidence is real and specific — a modest, memory-focused signal in older adults with diagnosed decline, not an all-purpose brain enhancer.

Where it sits relative to what we already sell

This lands in similar territory to Bacopa monnieri in our range evaluations — a real, specific effect on memory in a defined population, rather than the broad "focus and clarity" framing most brain-health marketing leans on. Bacopa's effect takes 6–12 weeks of continuous use to show up and centers on processing speed and working memory in a broader adult population; phosphatidylserine's clearest effect centers more tightly on memory itself, in a population already showing decline. Neither is the kind of same-day change that sells well, which is roughly the point of why we don't sell "brain blends".

What this means if you're actually evaluating it

The practical upshot is narrower than most marketing copy: the evidence supports phosphatidylserine as a memory-focused option for older adults who are already noticing decline — not as a general-purpose cognitive enhancer for a healthy 30-year-old who wants an edge before a big presentation. The dose range with the most trial support sits at 100–300mg/day, typically split across two or three servings, sustained for at least six weeks and more likely three months or longer before judging results.¹ None of the trials behind this evidence tested phosphatidylserine as a short-term or as-needed aid, so that's not a use case the data can speak to either way. And the effect size to expect, on the best available pooled estimate, is small.

Bottom line

Phosphatidylserine has genuine trial support for improving memory specifically in older adults already showing cognitive decline, at a small pooled effect size and on moderate-quality evidence. It's a real, if narrow, positive result — not the all-purpose brain enhancer it's often sold as. Worth knowing, too: the soy- or sunflower-derived PS in today's supplements isn't identical to the bovine cortex form used in the original research, and the regulatory paperwork behind the sunflower form is thinner than it's usually made to sound.

Phosphatidylserine is one of the ingredients in Cognitive Support, where it sits inside a 255mg proprietary blend alongside seven others. The per-ingredient amounts in that blend are not disclosed on the label, so we can't tell you how much phosphatidylserine a serving contains — and we're not going to imply the 100–300mg trial range above applies to it, because we can't show that it does. If the studied dose is what you're after, a single-ingredient phosphatidylserine product with the milligrams printed on the panel is the honest way to get it.

This article is for informational purposes only and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Speak with a healthcare provider before starting any new supplement, especially if you take medication or have an existing health condition.

References

Kang EY, Cui F, et al. Effect of phosphatidylserine on cognitive function in the elderly: A systematic review and meta-analysis. Korean Journal of Food Science and Technology, 2022;54(1):52-58. koreascience.kr
GRAS Notice No. GRN 000636, "Phosphatidylserine derived from sunflower lecithin," notifier ECA Healthcare, Inc. Filed 29 March 2016; closed 1 July 2016 — FDA ceased to evaluate at the notifier's request. FDA GRAS Notice Inventory. fda.gov GRAS Notice Inventory
Duan H, Xu N, Yang T, et al. Effects of a food supplement containing phosphatidylserine on cognitive function in Chinese older adults with mild cognitive impairment: A randomized double-blind, placebo-controlled trial. Journal of Affective Disorders, 2025;369:1-10. pubmed.ncbi.nlm.nih.gov/39317299